RBC Capital Markets set a $113.00 price objective on Incyte Corporation and gave the stock a "buy" rating in a research note on Monday, October 24th. Finally, Credit Suisse Group started coverage on Incyte Corporation …
Corporation
Combining all the ratings on Incyte Corporation (NASDAQ:INCY), the current mean stands at 1.18. The institutional investor owned 357,295 shares of the biopharmaceutical company's stock after buying an …
NASDAQ
Bearish analyst finds the equity at $92 within the imminent fiscal, while a bullish professional expects the stock at $140, within the same period. On analyst ratings scale of 1 to 5, Incyte Corporation (NASDAQ:INCY) has a …
Incyte Corporation
Jefferies Group LLC increased their price target on Incyte Corporation to $140.00 in a research report on Wednesday. Raymond James Upgrades the company's stock to Outperform on 9/29/16 with no specific Price …
Incyte Corporation
The parties have also entered into a separate Stock Purchase agreement whereby Incyte will purchase 10 million shares of Agenus common stock today at $6 per share. “The antibody discovery collaboration between Incyte
Massachusetts
That’s not all, as both have also signed up to a separate stock purchase agreement that sees Incyte buy 10 million shares of Agenus common …
Agenus
$274.5 million co's 1.25 pct notes due 2020 * Incyte Corp - agreement in exchange for an aggregate of 10.6 …
Reuters
The parties have also entered into a separate Stock Purchase agreement whereby Incyte will purchase 10 million shares of Agenus common stock today at $6 per share. 'The antibody discovery collaboration between Incyte
Agreement
Feb 14 (Reuters) - Incyte Corp : * Incyte and Agenus amend collaboration agreement ... of each approved product * Incyte Corp - parties also entered into separate stock purchase agreement whereby Incyte will …
Incyte Corp